Ivy Foundation Awards $3 Million for Brain Tumor Research at Barrow
(August 2014) -- The Ben & Catherine Ivy Foundation awarded a $3-million grant to a three- way research effort between Barrow Neurological Institute, Translational Genomics Research Institute (TGen) and Nemucore Medical Innovations Inc. to identify more effective treatments for brain tumors.
One of the goals of the grant is to enable Barrow, TGen and Nemucore to work collaboratively to identify new medications that can bridge the body’s blood-brain barrier, which typically impedes intravenous cancer drugs from reaching brain tumors. Researchers will target therapies delivered by nanotechnology systems to treat glioblastoma, the most common and most aggressive form of malignant brain tumors.
The project is an example of translational research, which aims to translate laboratory successes into effective patient care as quickly as possible.
“We are excited about this innovative approach to research,” said Catherine Ivy, founder and president of the Ivy Foundation. “Knowing there is a tangible way to develop therapies specific to the needs of patients will enhance the care and treatment of every brain tumor patient—and that is priceless.”
Based in Scottsdale, Ariz., the Ben & Catherine Ivy Foundation was founded in 2005 after Ben Ivy lost his battle with glioblastoma. Since then, the
organization has contributed more than $50 million to research to improve and lengthen the lives of brain tumor patients.
“Our first and foremost goal is to improve the prospects for patients diagnosed with glioblastoma and to translate our academic science into safe and effective therapies,” said Rachael Sirianni, PhD, principal investigator at the Barrow Brain Tumor Research Center. “This innovative partnership and the funding provided by the Ivy Founda- tion will make it possible to bring for- ward academic research to benefit patients at Barrow and elsewhere.”